The Chronic Lymphocytic Leukemia Channel on VJHemOnc is an independent medical education platform, supported with funding from AstraZeneca (Diamond), AbbVie (Platinum), BeOne Medicines (Silver) and Lilly (Silver). Supporters have no influence on the production of content. The levels of sponsorship listed are reflective of the amount of funding given.
EHA 2023 | Updated analysis of BELLWAVE-001: nemtabrutinib in R/R CLL
Farrukh Awan, MD, UT Southwestern Medical Center, Dallas, TX, gives an update on the Phase I/II study BELLWAVE-001 (NCT03162536) evaluating the non-covalent BTK inhibitor nemtabrutinib in patients with chronic lymphocytic leukemia (CLL) who have progressed following a BTK inhibitor or/and a BCL-2 inhibitor. The study reported encouraging response rates with a limited incidence of grade ≥ 3 adverse events. This interview took place at the 28th Congress of the European Hematology Association (EHA) 2023 in Frankfurt, Germany.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
